Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Aug 19:12:118.
doi: 10.1186/1475-2840-12-118.

Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study

Li-Nong Ji  1 , Chang-Yu Pan, Ju-Ming Lu, Hong Li, Qiang Li, Qi-Fu Li, Yong-De Peng, Hao-Ming Tian, Chen Yao, Zhi-Gang Zhao, Ru-Ya Zhang, Xiang-Ling Wang, Lei Wang; VISION Study Group
Affiliations
Clinical Trial

Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study

Li-Nong Ji et al. Cardiovasc Diabetol. .

Abstract

Background and aim: Limitations of the currently recommended stepwise treatment pathway for type 2 diabetes mellitus (T2DM), especially the failure of monotherapies to maintain good glycemic control, have prompted use of early, more aggressive combination therapies.The VISION study is designed to explore the efficacy and safety of vildagliptin as an add-on to metformin therapy compared with up-titration of metformin monotherapy in Chinese patients with T2DM.

Methods: VISION, a 24-week, phase 4, prospective, randomized, multicenter, open-label, parallel-group study, will include 3312 Chinese T2DM patients aged ≥18 years who are inadequately controlled (6.5% >HbA1c ≤9%) by metformin (750-1000 mg/day). Eligible patients will be randomized to receive either vildagliptin plus metformin or up-titration of metformin monotherapy (5:1). Patients will also be subgrouped (1:1:1:1) based on their age and body mass index (BMI): <60 years and <24 kg/m²; <60 years and ≥24 kg/m²; ≥60 years and <24 kg/m²; and ≥60 years and ≥24 kg/m².

Conclusion: The VISION study will test the hypothesis that early use of combination therapy with vildagliptin and metformin will provide good glycemic control and will be better tolerated than up-titration of metformin monotherapy. The study will also correlate these benefits with age and BMI.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Design of the VISION study.
See this image and copyright information in PMC

References

    1. Zinman B. Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time? Am J Med. 2011;124(Suppl 1):19–34. - PubMed
    1. World Health Organization. Diabetes key facts. http://www.who.int/mediacentre/factsheets/fs312/en/index.html.
    1. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, HE J. China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362:1090–1101. doi: 10.1056/NEJMoa0908292. - DOI - PubMed
    1. Niswender K. Early and aggressive initiation of insulin therapy for type 2 diabetes: what is the evidence? Clin Diabetes. 2009;27:60–68. doi: 10.2337/diaclin.27.2.60. - DOI
    1. Lebovitz HE. Type 2 diabetes mellitus – current therapies and the emergence of surgical options. Nat Rev Endocrinol. 2011;7:408–419. doi: 10.1038/nrendo.2011.10. - DOI - PubMed

Publication types

MeSH terms